Collaborative Arrangement, Exclusivity Period

No definition available.

Name:	dyai_CollaborativeArrangementExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Number of Antibodies and Vaccines For Development And Commercialization

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementNumberofAntibodiesandVaccinesForDevelopmentAndCommercialization
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Option To Extend Exclusivity Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOptionToExtendExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Option to Obtain Exclusive Commercial Sub-License For Number of Proteins

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOptiontoObtainExclusiveCommercialSubLicenseForNumberofProteins
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Ownership Interest Consideration Receivable Upon Extension Of Exclusivity Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementOwnershipInterestConsiderationReceivableUponExtensionOfExclusivityPeriod
Namespace Prefix:	dyai_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Research Funding, Milestone Payments And Royalties, Period

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementResearchFundingMilestonePaymentsAndRoyaltiesPeriod
Namespace Prefix:	dyai_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=dyai_SerumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=dyai_NovovetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent Events (Details) - Subsequent Event	May 07, 2019 antibody_and_vaccine protein	May 05, 2019	Apr. 26, 2019
Serum \| Collaborative Arrangement
Subsequent Event [Line Items]
Number of antibodies and vaccines for development and commercialization \| antibody_and_vaccine	12
Option to obtain exclusive commercial sub-license for number of proteins \| protein	12
Research funding, milestone payments and royalties, period	15 years
Novovet
Subsequent Event [Line Items]
Equity percentage			20.00%
Alphazyme
Subsequent Event [Line Items]
Equity percentage		7.50%
Ownership interest consideration receivable upon extension of exclusivity period		2.50%
Alphazyme \| Collaborative Arrangement
Subsequent Event [Line Items]
Exclusivity period		18 months
Option to extend exclusivity period		12 months